Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126058351 | 12605835 | 1 | I | 20160723 | 20160729 | 20160729 | EXP | PHHY2016BR103087 | NOVARTIS | 0.00 | F | Y | 64.00000 | KG | 20160729 | MD | BR | BR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126058351 | 12605835 | 1 | PS | DIOVAN HCT | HYDROCHLOROTHIAZIDEVALSARTAN | 1 | Oral | 1 DF (160 MG), QD | Y | 1601676 | 20818 | 1 | DF | TABLET | QD | ||||
| 126058351 | 12605835 | 2 | SS | DIOVAN | VALSARTAN | 1 | Oral | 80 MG, BID | 0 | 80 | MG | TABLET | BID |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126058351 | 12605835 | 1 | Hypertension |
| 126058351 | 12605835 | 2 | Hypertension |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126058351 | 12605835 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126058351 | 12605835 | Blood pressure inadequately controlled | |
| 126058351 | 12605835 | Blood sodium decreased | |
| 126058351 | 12605835 | Ovarian cyst |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |